thyssenkrupp nucera (NCH2) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
9 Jul, 2026Opening remarks and agenda
Introduced new board members and thanked outgoing members for their contributions.
Outlined the meeting format, emphasizing transparency, shareholder rights, and technical participation details.
Confirmed the presence of auditors and notary, and explained voting procedures and agenda items.
Board and executive committee updates
Noted significant changes in the Supervisory Board, including new appointments and expertise added in 2025.
Highlighted regular and transparent communication between the management and supervisory boards.
Emphasized ongoing governance improvements and compliance with regulatory requirements.
Financial performance review
Reported over EUR 845 million in revenue for fiscal year 2024/2025, with positive EBIT and improved free cash flow.
Achieved a 65% equity ratio and EUR 680 million in available liquidity, supporting financial resilience.
Share price stabilized after volatility, reflecting industry trends.
Implemented strict cost discipline, improved project mix, and increased R&D investment.
Latest events from thyssenkrupp nucera
- Q2 sales up 31% YoY, EBIT and net income improved, FY guidance confirmed.NCH2
Q2 20258 Jul 2026 - Q1 sales and EBIT declined, but guidance and order momentum remain strong.NCH2
Q1 20268 Jul 2026 - Q2 order intake soared while sales and EBIT fell; outlook and liquidity remain robust.NCH2
Q2 202626 May 2026 - Industrial-scale electrolysis leader with strong growth, innovation, and ESG focus.NCH2
Investor presentation13 May 2026 - Order intake guidance raised to €550–850m, but sales and EBIT guidance lowered for FY 2025/26.NCH2
Status update18 Mar 2026 - Record chlor-alkali sales and improved margins offset green hydrogen softness; outlook cautious.NCH2
Q4 202513 Feb 2026 - Record sales and robust backlog, but AWE outlook clouded by regulatory and market delays.NCH2
Q3 20241 Feb 2026 - Record sales and resilient AWE and CA growth drive strong performance amid market challenges.NCH2
Q4 202411 Jan 2026 - Record Q1 sales and EBIT growth, with strong outlook and robust order backlog.NCH2
Q1 202523 Dec 2025